Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

1,739 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Combination of exercise and GLP-1 receptor agonist treatment reduces severity of metabolic syndrome, abdominal obesity, and inflammation: a randomized controlled trial.
Sandsdal RM, Juhl CR, Jensen SBK, Lundgren JR, Janus C, Blond MB, Rosenkilde M, Bogh AF, Gliemann L, Jensen JB, Antoniades C, Stallknecht BM, Holst JJ, Madsbad S, Torekov SS. Sandsdal RM, et al. Among authors: holst jj. Cardiovasc Diabetol. 2023 Feb 25;22(1):41. doi: 10.1186/s12933-023-01765-z. Cardiovasc Diabetol. 2023. PMID: 36841762 Free PMC article. Clinical Trial.
The effects of postprandial exercise and meal glycemic index on plasma glucose and glucoregulatory hormone responses after Roux-en-Y gastric bypass.
Ternhamar T, Møller A, Martinussen C, Svane MS, Hindsø M, Jørgensen NB, Dirksen C, Jensen JB, Hartmann B, Holst JJ, Kiens B, Madsbad S, Bojsen-Møller KN. Ternhamar T, et al. Among authors: holst jj. Am J Physiol Endocrinol Metab. 2023 Nov 1;325(5):E540-E551. doi: 10.1152/ajpendo.00176.2023. Epub 2023 Sep 27. Am J Physiol Endocrinol Metab. 2023. PMID: 37755455
Markers of Glucagon Resistance Improve With Reductions in Hepatic Steatosis and Body Weight in Type 2 Diabetes.
Kjeldsen SAS, Thomsen MN, Skytte MJ, Samkani A, Richter MM, Frystyk J, Magkos F, Hansen E, Thomsen HS, Holst JJ, Madsbad S, Haugaard SB, Krarup T, Wewer Albrechtsen NJ. Kjeldsen SAS, et al. Among authors: holst jj. J Endocr Soc. 2023 Sep 21;7(11):bvad122. doi: 10.1210/jendso/bvad122. eCollection 2023 Oct 9. J Endocr Soc. 2023. PMID: 37818402 Free PMC article.
Neprilysin activity is increased in metabolic dysfunction-associated steatotic liver disease and normalizes after bariatric surgery or GLP-1 therapy.
Kjeldsen SAS, Gluud LL, Werge MP, Pedersen JS, Bendtsen F, Alexiadou K, Tan T, Torekov SS, Iepsen EW, Jensen NJ, Richter MM, Goetze JP, Rungby J, Hartmann B, Holst JJ, Holst B, Holt J, Gustafsson F, Madsbad S, Svane MS, Bojsen-Møller KN, Wewer Albrechtsen NJ. Kjeldsen SAS, et al. Among authors: holst b, holst jj. iScience. 2023 Oct 12;26(11):108190. doi: 10.1016/j.isci.2023.108190. eCollection 2023 Nov 17. iScience. 2023. PMID: 37953952 Free PMC article.
The role of empagliflozin-induced metabolic changes for cardiac function in patients with type 2 diabetes. A randomized cross-over magnetic resonance imaging study with insulin as comparator.
Thirumathyam R, Richter EA, van Hall G, Holst JJ, Fenger M, Gøtze JP, Dixen U, Vejlstrup N, Madsbad S, Madsen PL, Jørgensen NB. Thirumathyam R, et al. Among authors: holst jj. Cardiovasc Diabetol. 2024 Jan 6;23(1):13. doi: 10.1186/s12933-023-02094-x. Cardiovasc Diabetol. 2024. PMID: 38184612 Free PMC article. Clinical Trial.
Healthy weight loss maintenance with exercise, GLP-1 receptor agonist, or both combined followed by one year without treatment: a post-treatment analysis of a randomised placebo-controlled trial.
Jensen SBK, Blond MB, Sandsdal RM, Olsen LM, Juhl CR, Lundgren JR, Janus C, Stallknecht BM, Holst JJ, Madsbad S, Torekov SS. Jensen SBK, et al. Among authors: holst jj. EClinicalMedicine. 2024 Feb 19;69:102475. doi: 10.1016/j.eclinm.2024.102475. eCollection 2024 Mar. EClinicalMedicine. 2024. PMID: 38544798 Free PMC article.
Effects of 3 months of 10-h per-day time-restricted eating and 3 months of follow-up on bodyweight and cardiometabolic health in Danish individuals at high risk of type 2 diabetes: the RESET single-centre, parallel, superiority, open-label, randomised controlled trial.
Quist JS, Pedersen HE, Jensen MM, Clemmensen KKB, Bjerre N, Ekblond TS, Uldal S, Størling J, Wewer Albrechtsen NJ, Holst JJ, Torekov SS, Nyeland ME, Vistisen D, Jørgensen ME, Panda S, Brock C, Finlayson G, Blond MB, Færch K. Quist JS, et al. Among authors: holst jj. Lancet Healthy Longev. 2024 May;5(5):e314-e325. doi: 10.1016/S2666-7568(24)00028-X. Epub 2024 Apr 5. Lancet Healthy Longev. 2024. PMID: 38588687 Free article. Clinical Trial.
1,739 results